Physician profile
Archana Chandra
NPI 1134198013
$2,771.79
in general payments reported to CMS, 2019-2025
32 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $280 · 2021: $572 · 2022: $423 · 2023: $459 · 2024: $345 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Consulting Fee: $15.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.33 |
| Consulting Fee | $15.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $523.99 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $337.73 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $295.82 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.34 | 2019-2025 | Jardiance |
| Amgen INC. | $197.84 | 2019-2024 | Evenity, Prolia, Repatha |
| Stryker Corporation | $140.82 | 2022 | |
| Astellas Pharma US INC | $133.23 | 2020-2025 | Veozah |
| Lilly USA, LLC | $92.78 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.10 | 2021-2024 | Trulance, Xifaxan |
| Pfizer INC. | $76.47 | 2020-2024 | |
| Abbott Laboratories | $62.62 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Abbvie INC. | $60.90 | 2024-2025 | |
| Exact Sciences Corporation | $51.94 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $48.76 | 2020-2024 | Nuzyra |
| Medtronic, INC. | $38.74 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $35.95 | 2022 | |
| Eisai INC. | $34.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.18 | 2019-2021 | |
| Smith+Nephew, INC. | $32.07 | 2019-2024 | Grafix Pl, Oasis |
| Melinta Therapeutics, LLC | $28.08 | 2019-2021 | |
| Convatec INC. | $25.11 | 2023 | |
| Janssen Pharmaceuticals, INC | $24.19 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2025 | Gvoke Hypopen |
| Genentech USA, INC. | $20.02 | 2020 | |
| Kci USA, INC. | $17.23 | 2021 | |
| Si-Bone, INC. | $16.78 | 2025 | |
| Sumitomo Pharma America, INC. | $16.44 | 2023 | Gemtesa |
| Radius Health, INC. | $15.85 | 2019 | |
| Reprise Biomedical, INC. | $15.83 | 2024 | Miro3d |
| Allergan, INC. | $13.54 | 2019 | |
| Aytu Biopharma, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.